Maria Moscvin (@MMoscvin) header
Maria Moscvin (@MMoscvin) profile picture
Chicago, IL
Joined July 2020
Photo by Maria Moscvin (@MMoscvin)Photo by Maria Moscvin (@MMoscvin)Photo by Maria Moscvin (@MMoscvin)Photo by Maria Moscvin (@MMoscvin)Photo by Maria Moscvin (@MMoscvin)Photo by Maria Moscvin (@MMoscvin)Photo by Maria Moscvin (@MMoscvin)Photo by Maria Moscvin (@MMoscvin)Photo by Maria Moscvin (@MMoscvin)Photo by Maria Moscvin (@MMoscvin)
Maria Moscvin retweeted
FDA grants accelerated approval to neladalkib (NVL-655) for advanced ALK positive NSCLC with prior TKI therapy. Based on ALKOVE-1 study - post alectinib RR 49%, more than half of responses ongoing at a year. Favorable tox profile. New best in class? fda.gov/drugs/cancer-approva…
3
15
2
53
4,353
Huge work by @marinagarassino, @PrelajArsela and I3LUNG team!
November is #LungCancerAwarenessMonth! A multimodal AI model can now predict immunotherapy outcomes for advanced NSCLC better than standard biomarkers. This landmark international study of 2,396 patients offers major new hope for lung cancer. #AIinCancer ow.ly/pG5E5107p7i
3
157
Great work by @eripietroluongo and @FabioSalomone22 we presented at #ITMIG26 Only 7% of thymic epithelial tumour trials assessed PROs, despite 96% of daily-life-limiting symptoms lacking objective correlates. Time to put patients’ voices at the heart of toxicity assessment #LALCA26 #PatientReportedOutcomes #QoL
5
9
705
Maria Moscvin retweeted
Can MTAP deletion become an actionable Achilles’ heel in cancer? Pleased to share our review in The Oncologist on the MTAP–PRMT5 synthetic lethal axis: MTA-cooperative inhibitors, early clinical signals, biomarkers and resistance. @gbanna74 @OncJournal 🔗 doi.org/10.1093/oncolo/oyag4… kudos to the co-authors for their effort @Maxime_Borgeaud @mihaela_aldea dr Koessler and Dr Genoud @hug_ge @DOncologie
10
37
1,309
Every three minutes, someone is diagnosed with #lungcancer. But today, the outlook is better than ever, thanks in part to clinical trials that provide patients with the newest targeted treatments, including immunotherapy. 🫁 #LungCancerAwareness #lcsm uchicagomedicine.org/cancer/…
1
5
9
310
We are hiring! @PennCancer @Penn @PennMedicine is seeking Assistant Professors in Thoracic Oncology (Academic Clinician Track). Join our team to deliver outstanding patient care, educate the next generation of oncologists, and advance excellence in lung cancer care. apply.interfolio.com/196021
2
19
57
3,952
🔥AI-based prediction of actionable genomic alterations from H&E-stained slides — Perspective 🆙 @Nature_NPJ Precision Oncology 🎯Deep learning predicts AGAs (e.g., EGFR in NSCLC, FGFR in urothelial) directly from routine H&E; EAGLE & ANNAR trials 🎯Near-instant, non-destructive triage for molecular testing & trials at diagnosis; pragmatic integration pathway outlined 🎙Dr. Woochan Hwang @VivekSubbiah #LCSM @OncoAlert @Larvol @EGFRResisters nature.com/articles/s41698-0…
11
35
2,547
Are we seeing the ramp-up for thymic tumors similar to what happened for lung cancer? We owe our patients more innovative tools, therapeutic avenues, and closer collaborations, and #ITMIG26 is all about that.
1
1
5
510
Dr. @ajuloorimd discussing challenging cases of thymic tumors at #ITMIG26 with giants in the field Dr. Loehrer, Dr. Detterbeck and Dr. Arrossi. @UCCancerCenter @UChicagoHemOnc
1
4
421
Maria Moscvin retweeted
📓 Final PECATI trial supports PEMBRO + LENVATINIB in pretreated met B3 thymoma & thymic Ca. 📊 mINV-PFS: 22 mo | OS: 40 mo 🚀 Can IO, ADCs & bispecifics move to 1st line? 💪🏻 More academic & pharma collaboration is needed in rare thoracic malignancies! 🔗 authors.elsevier.com/a/1o6FL…
🤖 Made with AI
3
22
56
2,117
In thymoma, autoimmunity affects 40% of pts and may share one mechanism @NEJM: AIRE loss → increase IFNγ–JAK–STAT pathway mimicking APS-1, with decrease in IFNγ and CXCL9 upon Ruxolitinib. Antitumor activity was not evaluated, so caution is needed. nejm.org/doi/10.1056/NEJMc26…
2
262
Dr. @marinagarassino has a new paper out in @Annals_Oncology about the KEYNOTE-671 study for non-small-cell lung cancer-- an incredibly important study for the treatment of early stage disease! Read it at doi.org/10.1016/j.annonc.202… #AtTheForefront #CancerCare #LungCancer
3
1
289
Maria Moscvin retweeted
The latest version of the ASCO Multiple Myeloma Living Guideline is out! All published phase 3 data is reviewed every 8 weeks and recommendations are updated in real-time. We are continuing to refine algorithms for relapsed/refractory myeloma as time goes on. ascopubs.org/guidelines/trea…
4
38
2
136
15,370
Maria Moscvin retweeted
ASH welcomes its newly elected Executive Committee members! 👏 Bringing extensive experience and a shared commitment to advancing hematology, these leaders will help guide the Society's work in the years ahead. Read the full announcement: ow.ly/1TWf5100YrV
1
6
1
47
5,256
Another presentation Dr. @marinagarassino from @UCCancerCenter @UChicagoMed with biomarker analysis of KEYNOTE-671 for resectable early stage NSCLC.
1
4
1
6
821
Our own @marinagarassino @UCCancerCenter @UChicagoMed chair of the Thymic Tumors state of the art and addition of Ivonescimab in TC 1L and Rivoceranib Thymoma/TC further lines
1
6
9
458
Maria Moscvin retweeted
Presented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: nej.md/4iveIgW @myESMO
9
149
32
506
76,740
Kicking off #ESMO2026 with Alessandra Pedrocchi explaining the safety brakes we need to generate before employing AI agents in oncology
1
3
291